iMediSync Announces ‘iSyncWave’ EEG Scanner Receives FDA 510k clearance

iMediSync announced that iSyncWave, the company’s medical device EEG scanner, has been granted 510k clearance from the US Food and Drug Administration (FDA) on August 10th.

According to iMediSync, iSyncWave is a dry EEG scanner that does not require the use of electrode gel. It is not only easy to wear the device and measure EEG, but the size of the device can also be adjusted to accommodate various head shapes and align with the internationally standardized 10-20 system. Furthermore, iSyncWave analyzes the QEEG (Quantitative Electroencephalogram) in a short period of time through big data based automatic cloud analysis system.

This device was recently registered as an innovative prototype product by the Public Procurement Service in South Korea and was introduced to the mobile medical checkup service at Pusan National University Hospital. Data is continuously collected from patients with various diseases and illnesses (stroke, Parkinson’s, etc.) at leading university hospitals in South Korea, such as Seoul National University Hospital and Asan Medical Center.

In September, iSyncWave will be presented at the University of Oxford EEG seminar for children with developmental disabilities.

Following the FDA 510k clearance, iMediSync plans to increase and expand overseas sales.

Seungwan Kang, the CEO of iMediSync stated, “After CES 2022 and AAIC (Alzheimer’s Association International Conference), we are receiving many inquiries from the US, Europe, Australia, and other countries, particularly around research and clinical introduction from leading universities and institutions around the world. With FDA 510k clearance, we can provide product information and conduct collaborative research to sell iSyncWave. We are also preparing the CE (EU), TGA (Australia) and PMDA (Japan) registrations for countries that require registration other than from the FDA for import.”

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.


"Receiving this first FDA clearance for our retinal camera is not just a milestone, it's a leap forward in our quest to safeguard the vision of millions," said Dr. Patrick Sauvageau, optometrist, CEO, and co-founder of Zilia. "We're now focused on obtaining De Novo classification for ocular oximetry, a breakthrough biomarker that promises to revolutionize how we diagnose and manage a variety of ocular conditions."
The recent FDA clearances included Brainomix 360 e-CTP and Brainomix 360 e-MRI, both software modules that can support thrombolysis and thrombectomy treatment decisions, particularly for late-window patients who present to hospital more than 6-12 hours after stroke onset.
IONIC Health’s 510(k)-pending nCommand Lite technology is designed to include vendor-agnostic remote scanning capabilities. This strategic collaboration’s goal is to enable GE HealthCare to provide a multi-vendor, multi-modality remote scanning solution to healthcare systems and patients around the globe.
Silmitasertib works by inhibiting CK2 protein kinase, which have implicated in regulation of several signaling pathways that are important for innate immune responses. CK2 modulates inflammatory pathways, including NF-κB, PI3K–Akt–mTOR, and JAK–STAT.
"This is the culmination of years of research and development to deliver a medical device that helps improve the lives of patients suffering from spinal stenosis. Our recent move to larger premises in the Research Park at FAU will allow us to train our surgical and distribution partners to become increasingly competitive in the spinal implant device market,” said Peter Harris, founder and CEO of FloSpine.

By using this website you agree to accept Medical Device News Magazine Privacy Policy